UK Suspends Amgen's Tavneos Due to Unreliable Trial Data

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the use of Amgen's rare-disease drug Tavneos for new patients due to unreliable data from its main trial. The regulator plans to revoke UK approval for the drug on March 1, 2027.

Tavneos is used in combination with other medicines to treat severe autoimmune diseases that cause inflammation in small blood vessels and can damage the kidneys and lungs. Amgen developed Tavneos after acquiring ChemoCentryx for $3.7 billion in 2022.

The MHRA said unreliable data from the main trial meant it could no longer prove the drug's effectiveness or that its benefits outweighed the risks. The regulator has advised patients to continue treatment for six months while doctors consider alternatives, but not to stop without consulting a specialist.